/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
With a market cap of $384.6 billion, AbbVie Inc. (ABBV) is a global research-driven pharmaceutical company that develops and markets advanced therapies across immunology, oncology, neuroscience, and aesthetics. The Illinois-based company is known for blockbuster drugs like Humira and newer growth drivers such as Skyrizi and Rinvoq.
The drug giant is expected to announce its fiscal first-quarter earnings for 2026 on Friday, Apr. 24, before the market opens. Ahead of the event, analysts expect ABBV to report a profit of $3.01 per share on a diluted basis, up 22.4% from $2.46 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.